Loading...
Adding regional therapy to systemic agents, such as sorafenib, in the treatment of hepatocellular carcinoma (HCC) has yielded largely negative results compared to systemic therapy alone. With the advent of newer, potentially more effective systemic treatments, interest in studying the addition of regional therapy continues.
Investigators report results from a multicenter, open-label, randomized, phase 3 trial comparing treatment of HCC with the tyrosine kinase inhibitor lenvatinib with or without hepatic transarterial chemoembolization (TACE). Patients eligible to receive TACE could have a single tumor ≤10 cm or multiple tumors (≤10 foci) with <50% liver involvement. Patients were treated with daily lenvatinib (8 or 12 mg, dependent on weigh…